No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
Rent:
Rent this article for
JPY
Abstract
In Y2014, several new agents targeted to castration resistant(recurrent)prostate cancer; CRPC, are approved in Japan. Although such good news comes 2-3 years behind Western, it may improve the outcomes of the CRPC patients in Japan. In this issue, enzalutamide, abiraterone, and cabazitaxel are discussed by each experts from the productive industries. In addition, the experts from urological field and medical oncology field describe the role of each discipline.
Full text loading...
/content/article/0385-0684/41070/804